Vanguard Group Inc Inmune Bio, Inc. Transaction History

Vanguard Group Inc

$5.57 Trillion
Q4 2024

A detailed history of Vanguard Group Inc transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 738,201 shares of INMB stock, worth $6.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

738,201

Previous 720,712 2.43%

Holding current value

$6.34 Million

Previous $3.88 Million 11.25%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$4.4 - $6.43 $76,951 - $112,454	17,489 Added 2.43%	738,201 $3.45 Million
Q3 2024 Nov 13, 2024	BUY	$4.86 - $9.86 $449,127 - $911,192	92,413 Added 14.71%	720,712 $3.88 Million
Q2 2024 Aug 13, 2024	BUY	$7.15 - $11.84 $621,835 - $1.03 Million	86,970 Added 16.07%	628,299 $5.54 Million
Q4 2023 Feb 14, 2024	SELL	$6.6 - $11.52 $61,056 - $106,571	-9,251 Reduced 1.68%	541,329 $6.1 Million
Q2 2023 Aug 14, 2023	BUY	$6.5 - $10.09 $58,090 - $90,174	8,937 Added 1.65%	550,580 $5 Million
Q4 2022 Feb 10, 2023	BUY	$6.13 - $7.96 $1,501 - $1,950	245 Added 0.05%	541,643 $3.43 Million
Q3 2022 Nov 14, 2022	SELL	$6.04 - $10.44 $73,929 - $127,785	-12,240 Reduced 2.21%	541,398 $3.36 Million
Q1 2022 May 13, 2022	BUY	$6.42 - $11.39 $273,549 - $485,316	42,609 Added 8.34%	553,638 $4.66 Million
Q4 2021 Feb 14, 2022	BUY	$9.97 - $20.38 $619,316 - $1.27 Million	62,118 Added 13.84%	511,029 $5.21 Million
Q3 2021 Nov 12, 2021	BUY	$14.13 - $27.85 $985,468 - $1.94 Million	69,743 Added 18.39%	448,911 $8.72 Million
Q2 2021 Aug 13, 2021	BUY	$9.29 - $19.33 $3.52 Million - $7.33 Million	379,168 New	379,168 $6.66 Million

Others Institutions Holding INMB

# of Institutions

Shares Held

7.04M

Call Options Held

202K

Put Options Held

42.9K

View Full List

About Inmune Bio, Inc.

Ticker INMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,946,000
Market Cap $154M
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...

More about INMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Inmune Bio, Inc. Transaction History